Genetic/JJ
Variations/NNS
of/IN
ABCC2/NN
Gene/NN
Associated/VBN
with/IN
Adverse/JJ
Drug/NN
Reactions/NNS
to/TO
Valproic/JJ
Acid/NN
in/IN
Korean/JJ
Epileptic/JJ
Patients/NNS
./.
====================
The/DT
multidrug/JJ
resistance/NN
protein/NN
2/CD
(/(
MRP2/NN
,/,
ABCC2/NN
)/)
gene/NN
may/MD
determine/VB
individual/JJ
susceptibility/NN
to/TO
adverse/JJ
drug/NN
reactions/NNS
(/(
ADRs/NNS
)/)
in/IN
the/DT
central/JJ
nervous/JJ
system/NN
(/(
CNS/NN
)/)
by/IN
limiting/VBG
brain/NN
access/RB
of/IN
antiepileptic/JJ
drugs/NNS
,/,
especially/RB
valproic/JJ
acid/NN
(/(
VPA/NN
)/)
./.
====================
Our/PRP$
objective/NN
was/VBD
to/TO
investigate/VB
the/DT
effect/NN
of/IN
ABCC2/NN
polymorphisms/NNS
on/IN
ADRs/NNS
caused/VBD
by/IN
VPA/NN
in/IN
Korean/JJ
epileptic/JJ
patients/NNS
./.
====================
We/PRP
examined/VBD
the/DT
association/NN
of/IN
ABCC2/NN
single-nucleotide/JJ
polymorphisms/NNS
and/CC
haplotype/NN
frequencies/NNS
with/IN
VPA/NN
related/JJ
to/TO
adverse/VB
reactions/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
association/NN
of/IN
the/DT
polymorphisms/NNS
with/IN
the/DT
risk/NN
of/IN
VPA/NN
related/JJ
to/TO
adverse/VB
reactions/NNS
was/VBD
estimated/VBN
by/IN
logistic/JJ
regression/NN
analysis/NN
./.
====================
A/DT
total/JJ
of/IN
41/CD
(/(
24.4/CD
%/NN
)/)
patients/NNS
had/VBD
shown/VBN
VPA-related/JJ
adverse/JJ
reactions/NNS
in/IN
CNS/NN
,/,
and/CC
the/DT
most/JJS
frequent/JJ
symptom/NN
was/VBD
tremor/NN
(/(
78.0/CD
%/NN
)/)
./.
====================
The/DT
patients/NNS
with/IN
CNS/NN
ADRs/NNS
were/VBD
more/RBR
likely/JJ
to/TO
have/VB
the/DT
G/NN
allele/NN
(/(
79.3/CD
%/NN
vs./CC
62.7/CD
%/NN
,/,
p/NN
=/JJ
0.0057/CD
)/)
and/CC
the/DT
GG/NNS
genotype/NN
(/(
61.0/CD
%/NN
vs./CC
39.7/CD
%/NN
,/,
p/NN
=/JJ
0.019/CD
)/)
at/IN
the/DT
g.-1774delG/NN
locus/NN
./.
====================
The/DT
frequency/NN
of/IN
the/DT
haplotype/JJ
containing/VBG
g.-1774Gdel/NN
was/VBD
significantly/RB
lower/JJR
in/IN
the/DT
patients/NNS
with/IN
CNS/NN
ADRs/NNS
than/IN
without/IN
CNS/NN
ADRs/NNS
(/(
15.8/CD
%/NN
vs./CC
32.3/CD
%/NN
,/,
p/NN
=/JJ
0.0039/CD
)/)
./.
====================
Lastly/RB
,/,
in/IN
the/DT
multivariate/JJ
logistic/JJ
regression/NN
analysis/NN
,/,
the/DT
presence/NN
of/IN
the/DT
GG/NNS
genotype/NN
at/IN
the/DT
g.-1774delG/NN
locus/NN
was/VBD
identified/VBN
as/IN
a/DT
stronger/JJR
risk/NN
factor/NN
for/IN
VPA/NN
related/JJ
to/TO
ADRs/NNS
(/(
odds/NNS
ratio/NN
,/,
8.53/CD
;/:
95/CD
%/NN
confidence/NN
interval/JJ
,/,
1.04/CD
to/TO
70.17/CD
)/)
./.
====================
We/PRP
demonstrated/VBD
that/IN
ABCC2/NN
polymorphisms/NNS
may/MD
influence/VB
VPA-related/JJ
ADRs/NNS
./.
====================
The/DT
results/NNS
above/VBP
suggest/VBP
the/DT
possible/JJ
usefulness/NN
of/IN
ABCC2/NN
gene/NN
polymorphisms/NNS
as/IN
a/DT
marker/NN
for/IN
predicting/VBG
response/NN
to/TO
VPA-related/JJ
ADRs/NNS
./.
====================
Various/JJ
forms/NNS
of/IN
epilepsy/NN
are/VBP
among/IN
the/DT
most/JJS
common/JJ
serious/JJ
brain/NN
disorders/NNS
and/CC
present/JJ
through/IN
convulsion/NN
,/,
autonomic/JJ
movement/NN
,/,
impaired/JJ
consciousness/NN
,/,
and/CC
more/RBR
[/(
1/CD
]/)
./.
====================
These/DT
neurological/JJ
disorders/NNS
affect/VB
an/DT
estimated/VBN
42/CD
million/NN
people/NN
of/IN
all/DT
ages/NNS
worldwide/NN
[/(
2/CD
]/)
./.
====================
The/DT
blood-brain/NN
barrier/RBR
(/(
BBB/NN
)/)
has/VBZ
challenged/VBN
the/DT
treatment/NN
of/IN
epilepsy/NN
,/,
since/IN
many/JJ
antiepileptic/JJ
drugs/NNS
(/(
AEDs/NNS
)/)
are/VBP
not/RB
effectively/RB
distributed/VBN
to/TO
the/DT
vascular/JJ
endothelium/NN
or/CC
,/,
accordingly/RB
,/,
to/TO
their/PRP$
targets/NNS
in/IN
brain/NN
[/(
3/CD
,/,
4/CD
]/)
./.
====================
The/DT
BBB/NN
,/,
thought/VBN
to/TO
be/VB
the/DT
first-line/JJ
barrier/NN
to/TO
the/DT
disposition/NN
of/IN
drug/NN
from/IN
the/DT
blood/NN
to/TO
the/DT
brain/NN
[/(
5/CD
]/)
,/,
consists/VBZ
of/IN
the/DT
interplay/NN
of/IN
three/CD
major/JJ
microvascular/JJ
components/NNS
./.
====================
Tight/CD
junctions/NNS
between/IN
the/DT
endothelial/JJ
cells/NNS
constitute/VBP
the/DT
major/JJ
permeability/NN
barrier/NN
./.
====================
The/DT
overall/JJ
biology/NN
of/IN
the/DT
barrier/NN
is/VBZ
shaped/VBN
by/IN
the/DT
interactions/NNS
between/IN
the/DT
endothelium/NN
and/CC
the/DT
pericytes/smooth/DT
muscle/NN
cells/NNS
and/CC
the/DT
astrocyte/NN
foot/NN
processes/NNS
that/DT
cover/RB
most/JJS
of/IN
the/DT
abluminal/JJ
surface/NN
of/IN
the/DT
microvasculature/NN
[/(
6/CD
]/)
./.
====================
Drug/NN
pharmacokinetics/NNS
is/VBZ
controlled/VBN
by/IN
drug/NN
transporters/NNS
,/,
which/WDT
regulate/VBP
drug/NN
absorption/NN
,/,
distribution/NN
,/,
and/CC
excretion/NN
./.
====================
Drug/NN
transporters/NNS
are/VBP
considered/VBN
a/DT
second-line/JJ
barrier/NN
for/IN
limiting/VBG
drug/NN
disposition/NN
from/IN
the/DT
blood/NN
to/TO
the/DT
brain/NN
[/(
7/CD
]/)
./.
====================
In/IN
brain/NN
capillary/JJ
endothelial/JJ
cells/NNS
,/,
multidrug/JJ
resistance/NN
protein/NN
1/CD
(/(
MDR1/NN
)/)
;/:
multidrug/NN
resistance-associated/JJ
protein/NN
1/CD
(/(
MRP1/NN
)/)
,/,
MRP2/NN
,/,
MRP4/NN
,/,
and/CC
MRP5/NN
;/:
and/CC
breast/NN
cancer/NN
resistance/NN
protein/NN
(/(
BCRP/NN
)/)
are/VBP
among/IN
the/DT
many/JJ
drug/NN
transporters/VBZ
that/IN
might/MD
be/VB
expressed/VBN
at/IN
the/DT
luminal/JJ
side/JJ
of/IN
the/DT
membrane/NN
[/(
5/CD
,/,
8/CD
,/,
9/CD
]/)
./.
====================
MRP2/NN
,/,
in/IN
particular/JJ
,/,
is/VBZ
over-expressed/VBN
(/(
about/RB
225/CD
%/NN
greater/JJR
)/)
in/IN
drug-refractory/JJ
temporal/JJ
lobe/NN
epileptic/JJ
patients/NNS
with/IN
hippocampal/JJ
sclerosis/NN
(/(
HS/NN
)/)
[/(
5/CD
,/,
10-12/CD
]/)
./.
====================
Drug/NN
reactions/NNS
can/MD
be/VB
different/JJ
between/IN
individuals/NNS
with/IN
the/DT
same/JJ
AED/NN
blood/NN
concentrations/NNS
and/CC
therapeutic/JJ
levels/NNS
,/,
because/IN
drug/NN
distribution/NN
is/VBZ
influenced/VBN
by/IN
variable/JJ
levels/NNS
of/IN
drug/NN
transporters/NNS
./.
====================
MRP2/NN
is/VBZ
thought/VBN
to/TO
play/VB
a/DT
more/RBR
important/JJ
role/NN
in/IN
the/DT
distribution/NN
of/IN
AEDs/NNS
than/IN
other/JJ
transporters/NNS
in/IN
the/DT
epileptic/JJ
brain/NN
[/(
13/CD
]/)
./.
====================
MRP2/NN
has/VBZ
been/VBN
demonstrated/VBN
to/TO
transport/VB
many/JJ
AEDs/NNS
,/,
including/VBG
valproate/NN
(/(
VPA/NN
)/)
,/,
carbamazepine/JJ
(/(
CBZ/NN
)/)
,/,
phenytoin/NN
(/(
PHT/NN
)/)
,/,
and/CC
more/RBR
[/(
9/CD
,/,
14-17/CD
]/)
./.
====================
Valproic/JJ
acid/NN
has/VBZ
become/VBN
established/VBN
as/IN
one/CD
of/IN
the/DT
most/JJS
widely/RB
used/VBN
AEDs/NNS
in/IN
the/DT
treatment/NN
of/IN
both/DT
generalized/VBN
and/CC
partial/JJ
seizures/NNS
in/IN
adults/NNS
and/CC
children/NN
and/CC
is/VBZ
considered/VBN
to/TO
be/VB
a/DT
substrate/NN
of/IN
MRP2/NN
[/(
9/CD
,/,
14-17/CD
]/)
./.
====================
Probenecid/NN
,/,
an/DT
inhibitor/NN
of/IN
MRPs/NNS
,/,
has/VBZ
been/VBN
shown/VBN
to/TO
increase/VB
the/DT
concentration/NN
of/IN
valproic/JJ
acid/NN
in/IN
the/DT
brain/NN
[/(
18/CD
]/)
./.
====================
In/IN
animal/NN
models/NNS
,/,
TR-/JJ
rats/NNS
(/(
MRP2/NN
knockout/JJ
)/)
have/VBP
lower/JJR
VPA/NN
and/CC
VPA-glucuronide/NN
in/IN
their/PRP$
bile/JJ
than/IN
control/NN
Wistar/JJ
rats/NNS
(/(
which/WDT
intrinsically/RB
express/VBP
MRP2/NN
)/)
[/(
19/CD
]/)
./.
====================
Functional/JJ
polymorphisms/NNS
in/IN
genes/NNS
encoding/VBG
drug/NN
transporters/NNS
can/MD
alter/VB
AED/NN
uptake/NN
,/,
cerebral/JJ
distribution/NN
,/,
and/CC
efflux/NN
,/,
resulting/VBG
in/IN
individual/JJ
differences/NNS
in/IN
AED/NN
concentration/NN
and/CC
effectiveness/NN
and/or/CC
the/DT
occurrence/NN
of/IN
adverse/JJ
drug/NN
reactions/NNS
(/(
ADRs/NNS
)/)
./.
====================
Many/JJ
functional/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
have/VBP
been/VBN
reported/VBN
./.
====================
For/IN
example/NN
,/,
mRNA/NN
expression/NN
of/IN
the/DT
c.1446CG/NN
MRP2/NN
genotype/NN
was/VBD
recently/RB
revealed/VBD
to/TO
be/VB
higher/JJR
than/IN
the/DT
c.1446CC/NN
genotype/NN
in/IN
the/DT
liver/NN
[/(
20/CD
]/)
./.
====================
In/IN
addition/NN
,/,
the/DT
c.2302C/NN
>/JJR
T/NN
(/(
exon/NN
18/CD
,/,
Arg768Trp/NN
)/)
mutation/NN
is/VBZ
responsible/JJ
for/IN
Dubin-Johnson/NN
syndrome/NN
[/(
21/CD
,/,
22/CD
]/)
./.
====================
The/DT
c.2302C/NN
>/JJR
T/NN
and/CC
c.4348G/NN
>/JJR
A/DT
genotypes/NNS
correlate/VBP
with/IN
significantly/RB
lower/JJR
MRP2/NN
protein/NN
expression/NN
levels/NNS
compared/VBD
to/TO
wild-type/JJ
and/CC
V417I/NN
[/(
21/CD
]/)
./.
====================
The/DT
c.1249G/NN
>/JJR
A/NN
mutation/NN
significantly/RB
reduces/VBZ
the/DT
amount/NN
of/IN
MRP2/NN
mRNA/NN
in/IN
human/JJ
preterm/JJ
placentas/NNS
[/(
23/CD
]/)
./.
====================
The/DT
g.-1774delG/NN
polymorphism/NN
has/VBZ
been/VBN
linked/VBN
with/IN
toxic/JJ
hepatitis/NN
by/IN
our/PRP$
group/NN
[/(
24/CD
]/)
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
investigated/VBD
the/DT
association/NN
between/IN
the/DT
g.-1774delG/NN
MRP2/NN
genotype/NN
and/CC
ADRs/NNS
of/IN
the/DT
central/JJ
nervous/JJ
system/NN
(/(
CNS/NN
)/)
in/IN
VPA/NN
treatment/NN
groups/NNS
./.
====================
Subjects/NNS
====================
This/DT
retrospective/JJ
study/NN
included/VBD
168/CD
epileptic/JJ
Korean/JJ
patients/NNS
who/WP
received/VBD
VPA/NN
at/IN
Sinchon/JJ
and/CC
Gangnam/JJ
Severance/NN
Hospitals/NNS
./.
====================
Forty-one/CD
patients/NNS
demonstrated/VBD
VPA/NN
dose-related/JJ
ADRs/NNS
in/IN
the/DT
central/JJ
nervous/JJ
system/NN
(/(
dizziness/RB
,/,
headache/RB
,/,
somnolence/RB
,/,
diplopia/NN
,/,
dysarthria/NN
,/,
tremor/NN
,/,
etc/JJ
./.
====================
)/)
,/,
while/IN
the/DT
remainder/NN
(/(
n/NN
=/JJ
127/CD
)/)
did/VBD
not/RB
./.
====================
Patients/NNS
who/WP
were/VBD
diagnosed/VBN
with/IN
chronic/JJ
active/JJ
epilepsy/NN
,/,
West/NNP
syndrome/NN
,/,
Lennox-Gastaut/NNP
syndrome/NN
,/,
progressive/JJ
myoclonic/JJ
epilepsy/NN
,/,
tuberous/JJ
sclerosis/NN
,/,
Sturge-Weber/NN
syndrome/NN
,/,
hamartoma/NN
,/,
or/CC
brain/NN
tumors/NNS
were/VBD
excluded/VBN
./.
====================
There/EX
were/VBD
no/DT
statistical/JJ
differences/NNS
in/IN
age/NN
,/,
sex/NN
,/,
response/non-response/JJ
,/,
and/CC
sclerosis/NN
between/IN
the/DT
two/CD
groups/NNS
./.
====================
Demographic/JJ
characteristics/NNS
of/IN
the/DT
epileptic/JJ
patients/NNS
are/VBP
presented/VBN
in/IN
Table/JJ
1/CD
./.
====================
DNA/NN
from/IN
control/JJ
subjects/NNS
(/(
n/NN
=/JJ
110/CD
)/)
was/VBD
randomly/RB
selected/VBN
from/IN
the/DT
DNA/NN
bank/NN
of/IN
the/DT
Korea/NN
Pharmacogenomics/NNS
Research/NN
Network/NN
at/IN
Seoul/JJ
National/JJ
University/NN
./.
====================
Blood/NN
samples/NNS
were/VBD
collected/VBN
from/IN
each/DT
subject/JJ
,/,
and/CC
DNA/NN
was/VBD
extracted/VBN
using/VBG
a/DT
QIAamp/NN
DNA/NN
blood/NN
mini/NNS
kit/NN
(/(
Qiagen/NN
GmbH/NN
,/,
Hilden/JJ
,/,
Germany/NNP
)/)
./.
====================
Genetic/JJ
analysis/NN
====================
Polymorphisms/NNS
of/IN
the/DT
MDR1/NN
,/,
MRP/NN
,/,
and/CC
BCRP/NN
genes/NNS
in/IN
the/DT
Korean/JJ
population/NN
were/VBD
discovered/VBN
by/IN
denaturing/VBG
gradient/JJ
gel/NN
electrophoresis/NN
,/,
two-dimensional/JJ
gene/NN
scanning/NN
,/,
and/CC
direct/JJ
PCR/NN
using/VBG
methods/NNS
similar/JJ
to/TO
those/DT
described/VBN
in/IN
a/DT
previous/JJ
paper/NN
[/(
24/CD
]/)
./.
====================
Genotype/JJ
screening/NN
of/IN
each/DT
locus/NN
in/IN
control/JJ
and/CC
epileptic/JJ
patients/NNS
was/VBD
performed/VBN
by/IN
the/DT
SNaPshot/JJ
or/CC
SNaPIT/NN
method/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
,/,
according/VBG
to/TO
the/DT
protocols/NNS
supplied/VBD
by/IN
the/DT
manufacturer/NN
./.
====================
Statistical/JJ
analysis/NN
====================
Haploview/NN
software/JJ
(/(
version/NN
3.2/CD
)/)
was/VBD
used/VBN
to/TO
design/VB
MRP2/NN
haplotype/NN
constructs/NNS
and/CC
analyze/VB
major/JJ
or/CC
minor/JJ
haplotypes/NNS
based/VBN
on/IN
a/DT
standard/JJ
expectation-maximization/NN
algorithm/NN
./.
====================
Allele/DT
and/CC
genotype/NN
frequencies/NNS
of/IN
transporter/JJ
polymorphisms/NNS
were/VBD
assessed/VBN
using/VBG
chi-square/JJ
tests/NNS
(/(
version/NN
11.5/CD
for/IN
Windows/VBZ
;/:
SPSS/NN
Inc./NNP
,/,
Chicago/JJ
,/,
IL/NN
,/,
USA/NN
)/)
./.
====================
Logistic/JJ
regression/NN
====================
The/DT
strength/NN
of/IN
the/DT
association/NN
between/IN
dose-related/JJ
CNS/NN
ADR/NN
patients/NNS
and/CC
the/DT
presence/NN
of/IN
the/DT
G/NN
allele/NN
at/IN
the/DT
g.-1774/NN
region/NN
was/VBD
evaluated/VBN
as/IN
the/DT
odds/NNS
ratio/NN
(/(
OR/NN
)/)
obtained/VBN
with/IN
logistic/JJ
regression/NN
analysis/NN
(/(
SPSS/NN
version/NN
11.5/CD
)/)
./.
====================
ORs/NNS
were/VBD
adjusted/VBN
for/IN
gender/NN
,/,
age/NN
,/,
HS/NN
,/,
use/NN
of/IN
AEDs/NNS
(/(
larmotrigene/JJ
,/,
CBZ/NN
,/,
PHT/NN
,/,
and/CC
topiramate/NN
)/)
,/,
and/CC
the/DT
presence/NN
of/IN
the/DT
G/NN
allele/NN
at/IN
the/DT
g.-1774/NN
promoter/NN
region/NN
./.
====================
Cell/NN
culture/NN
====================
SH-SY5Y/NN
(/(
ATCC/NN
,/,
Manassas/JJ
,/,
VA/NN
,/,
USA/NN
)/)
,/,
a/DT
human/JJ
brain/NN
neuronal/JJ
cell/NN
line/NN
originated/VBN
from/IN
a/DT
neuroblastoma/NN
,/,
was/VBD
a/DT
gift/JJ
from/IN
Dr/NN
./.
====================
In/IN
Suk/NN
Kim/NN
,/,
Yonsei/NNP
University/NN
College/NN
of/IN
Medicine/NN
,/,
Seoul/JJ
,/,
Korea/NN
./.
====================
SH-SY5Y/NN
cells/NNS
were/VBD
maintained/VBN
with/IN
Dulbecco/NN
's/POS
modified/VBN
Eagle/JJ
medium/NN
supplemented/VBN
with/IN
10/CD
%/NN
fetal/JJ
bovine/NN
serum/NN
(/(
Invitrogen/NN
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
1/CD
%/NN
PS/NN
(/(
100/CD
units/NNS
penicillin/NN
,/,
100/CD
µg/VBG
streptomycin/NN
,/,
Gibco/NNP
,/,
Grand/CC
Island/CC
,/,
NY/NNP
,/,
YSA/NNP
)/)
and/CC
were/VBD
cultured/VBN
under/IN
preconfluent/JJ
monolayer/JJ
conditions/NNS
in/IN
100-mm-diameter/RBR
polyd-lysine-coated/JJ
culture/NN
dishes/NNS
at/IN
37℃/CD
with/IN
5/CD
%/NN
humidified/VBN
CO2/NN
./.
====================
Plasmid/NN
preparation/NN
of/IN
MRP2/NN
promoter/NN
====================
A/DT
pGL3/NN
basic/JJ
vector/NN
containing/VBG
the/DT
human/JJ
MRP2/NN
promoter/NN
region/NN
(/(
about/RB
2.3/CD
kb/NN
,/,
-2314/CD
to/TO
+348/CD
relative/JJ
to/TO
the/DT
translation/NN
initiation/NN
site/NN
)/)
was/VBD
constructed/VBN
by/IN
our/PRP$
group/NN
in/IN
a/DT
previous/JJ
study/NN
from/IN
homozygotic/JJ
persons/NNS
with/IN
MRP2/NN
haplotypes/NNS
1/CD
,/,
2/CD
,/,
and/CC
3/CD
[/(
24/CD
]/)
./.
====================
The/DT
g.-1774delG/NN
polymorphism/NN
is/VBZ
located/JJ
in/IN
haplotype/JJ
1/CD
,/,
and/CC
the/DT
g.-24C/NN
>/JJR
T/NN
polymorphism/NN
is/VBZ
located/JJ
in/IN
haplotype/JJ
3/CD
./.
====================
The/DT
reporter/NN
vector/NN
of/IN
a/DT
minor/JJ
haplotype/JJ
variant/JJ
containing/VBG
only/RB
the/DT
g.-1549G/NN
>/JJR
A/DT
variation/NN
was/VBD
constructed/VBN
using/VBG
mutagenic/JJ
primers/NNS
,/,
introducing/VBG
a/DT
-24/CD
T/NN
→/NN
C/NN
change/NN
to/TO
the/DT
plasmid/NN
of/IN
haplotype/JJ
3/CD
containing/VBG
both/CC
g.-1549G/NNS
>/JJR
A/DT
and/CC
g.-24C/NN
>/JJR
T/NN
variations/NNS
./.
====================
Haplotype/NN
2/CD
includes/VBZ
no/DT
polymorphism/NN
(/(
wild-type/JJ
)/)
./.
====================
In/IN
short/JJ
,/,
a/DT
total/JJ
of/IN
five/CD
clones/NNS
were/VBD
prepared/VBN
:/:
pGL3/NN
basic/JJ
;/:
haplotypes/NNS
1/CD
,/,
2/CD
,/,
and/CC
3/CD
;/:
and/CC
g.-1549A/NN
alone/RB
./.
====================
Dual/JJ
luciferase/NN
assay/NN
====================
The/DT
pGL3/NN
basic/JJ
vector/NN
containing/VBG
WT/NN
MRP2/NN
promoter/NN
variants/NNS
was/VBD
transfected/VBN
into/IN
SH-SY5Y/NN
cells/NNS
to/TO
measure/VB
the/DT
activity/NN
of/IN
the/DT
MRP2/NN
promoter/NN
with/IN
and/CC
without/IN
VPA/NN
(/(
P4543/NN
;/:
Sigma/NN
Aldrich/JJ
,/,
St./NNP
Louis/JJ
,/,
MO/NN
,/,
USA/NNP
)/)
./.
====================
The/DT
day/NN
before/IN
transfection/NN
,/,
0.2/CD
×/NN
106/CD
SH-SY5Y/NN
cells/NNS
were/VBD
seeded/VBN
in/IN
a/DT
12-well/NN
plate/VBP
in/IN
order/NN
to/TO
reach/VB
90-95/CD
%/NN
confluence/NN
at/IN
the/DT
time/NN
of/IN
transfection/NN
;/:
1.6/CD
µg/NN
of/IN
pGL3-MRP2/NN
,/,
including/VBG
the/DT
variants/NNS
and/CC
mock/VBP
,/,
was/VBD
added/VBN
to/TO
wells/NNS
with/IN
Lipofectamine/NN
2000/CD
(/(
Invitrogen/NN
)/)
./.
====================
Vector-containing/VBG
Renilla/NN
luciferase/NN
was/VBD
cotransfected/VBN
in/IN
order/NN
to/TO
confirm/VB
the/DT
transfection/NN
efficiency/NN
of/IN
the/DT
pGL3-MRP2/NN
vector/NN
./.
====================
After/IN
a/DT
3-/JJ
to/TO
5-h/JJ
incubation/NN
,/,
cells/NNS
were/VBD
washed/VBN
with/IN
phosphate-buffered/JJ
saline/NN
(/(
PBS/NN
;/:
Invitrogen/NN
)/)
and/CC
incubated/VBN
at/IN
37℃/CD
with/IN
5/CD
%/NN
humidified/VBN
CO2/NN
for/IN
24/CD
h./FW
Reporter/NN
activity/NN
was/VBD
measured/VBN
using/VBG
the/DT
Dual/JJ
Luciferase/NN
Reporter/NN
Assay/NN
system/NN
(/(
Promega/NNP
Corporation/NN
,/,
Madison/NNP
,/,
WI/NN
,/,
USA/NNP
)/)
./.
====================
After/IN
removing/VBG
the/DT
growth/NN
medium/NN
,/,
cells/NNS
were/VBD
washed/VBN
with/IN
PBS/NN
,/,
and/CC
the/DT
plates/NNS
were/VBD
placed/VBN
on/IN
a/DT
rocking/JJ
platform/NN
shaker/JJR
with/IN
250/CD
µL/NN
of/IN
1/CD
×/NN
passive/JJ
lysis/NN
buffer/NN
per/IN
well/RB
for/IN
15/CD
min/NN
./.
====================
Lysates/NNS
were/VBD
transferred/VBN
to/TO
an/DT
e-tube/NN
,/,
and/CC
luciferase/NN
binding/NN
was/VBD
performed/VBN
with/IN
50/CD
µL/NNS
LARII/NN
and/CC
10-50/CD
µL/NN
cell/NN
lysate/NN
in/IN
a/DT
96-well/JJ
assay/NN
plate/VBP
(/(
Costar/NN
;/:
Corning/NN
Incorp./NNP
,/,
Corning/VBG
,/,
NY/NN
,/,
USA/NNP
)/)
./.
====================
After/IN
10/CD
s/NNS
,/,
light/JJ
emission/NN
was/VBD
measured/VBN
using/VBG
a/DT
luminometer/NN
(/(
Berthold/JJ
Technologies/NNS
,/,
Wildbad/JJ
,/,
Germany/NNP
)/)
,/,
and/CC
Stop/NN
&/CC
Glo/NN
was/VBD
added/VBN
to/TO
each/DT
well/RB
to/TO
stop/VB
firefly/RB
luciferase/NN
activity/NN
and/CC
evoke/RB
Renilla/NN
luciferase/NN
activity/NN
./.
====================
SNP/NN
association/NN
with/IN
drug/NN
response/NN
or/CC
resistance/NN
====================
Drug/NN
resistance/NN
was/VBD
defined/VBN
as/IN
the/DT
occurrence/NN
of/IN
at/IN
least/JJS
four/CD
seizures/NNS
over/IN
the/DT
year/NN
before/IN
recruitment/NN
,/,
with/IN
trials/NNS
of/IN
more/RBR
than/IN
three/CD
appropriate/JJ
AED/NN
,/,
at/IN
maximal/JJ
tolerated/VBN
doses/NNS
,/,
based/VBN
on/IN
the/DT
occurrence/NN
of/IN
clinical/JJ
side/JJ
effects/NNS
at/IN
supra-maximal/JJ
doses/NNS
[/(
25/CD
]/)
./.
====================
The/DT
patients/NNS
were/VBD
classified/VBN
as/IN
either/CC
responsive/JJ
or/CC
resistant/JJ
to/TO
drug/NN
therapy/NN
./.
====================
We/PRP
did/VBD
not/RB
find/VB
any/DT
significant/JJ
associations/NNS
between/IN
the/DT
selected/VBN
drug/NN
transporter/NN
SNPs/NNS
and/CC
either/CC
group/NN
./.
====================
Clinical/JJ
characteristics/NNS
of/IN
epilepsy/NN
patients/NNS
====================
A/DT
total/JJ
of/IN
41/CD
(/(
24/CD
%/NN
)/)
epileptic/JJ
patients/NNS
had/VBD
ADRs/NNS
of/IN
the/DT
CNS/NN
,/,
and/CC
127/NN
(/(
76/CD
%/NN
)/)
epileptic/JJ
patients/NNS
did/VBD
not/RB
(/(
non-ADR/JJ
)/)
./.
====================
The/DT
demographic/JJ
characteristics/NNS
are/VBP
listed/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
gender/NN
frequency/NN
,/,
drug/NN
response/NN
,/,
and/CC
the/DT
average/NN
age/NN
of/IN
drug/NN
use/NN
between/IN
the/DT
two/CD
groups/NNS
were/VBD
similar/JJ
./.
====================
(/(
p/NN
>/JJR
0.05/CD
)/)
Subjects/NNS
without/IN
ADRs/NNS
used/VBN
fewer/JJR
drugs/NNS
than/IN
those/DT
with/IN
ADRs/NNS
(/(
p/NN
=/JJ
0.039/CD
)/)
./.
====================
The/DT
most/JJS
frequent/JJ
symptom/NN
out/RP
of/IN
14/CD
types/NNS
of/IN
ADRs/NNS
to/TO
VPA/NN
use/NN
was/VBD
tremors/NNS
(/(
78.0/CD
%/NN
)/)
./.
====================
Based/VBN
on/IN
logistic/JJ
regression/NN
,/,
ADRs/NNS
were/VBD
more/RBR
likely/JJ
to/TO
occur/VB
in/IN
patients/NNS
with/IN
g.-1774delG/NN
(/(
presence/NN
of/IN
G/NN
allele/NN
)/)
,/,
which/WDT
had/VBD
the/DT
highest/JJS
OR/NN
(/(
9.10/CD
)/)
among/IN
the/DT
considered/VBN
factors/NNS
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
Genetic/JJ
polymorphisms/NNS
of/IN
MRP2/NN
in/IN
the/DT
Korean/JJ
population/NN
====================
MRP/NN
polymorphisms/NNS
covering/VBG
all/DT
MRP2/NN
exons/NNS
,/,
exonintron/NN
junctions/NNS
,/,
and/CC
the/DT
promoter/NN
region/NN
up/IN
to/TO
-2.3/CD
Kb/NN
from/IN
the/DT
translation/NN
initiation/NN
site/NN
have/VBP
been/VBN
described/VBN
in/IN
the/DT
Korean/JJ
population/NN
[/(
24/CD
]/)
./.
====================
We/PRP
investigated/VBD
11/CD
of/IN
the/DT
polymorphisms/NNS
from/IN
previous/JJ
studies/NNS
in/IN
110/CD
healthy/JJ
control/NN
people/NN
and/CC
168/CD
epileptic/JJ
patients/NNS
./.
====================
We/PRP
found/VBD
four/CD
promoter/NN
,/,
four/CD
exonic/JJ
,/,
and/CC
three/CD
intronic/JJ
polymorphisms/NNS
among/IN
them/PRP
./.
====================
Relationship/NN
between/IN
genotypes/NNS
of/IN
MRP2/NN
and/CC
CNS/NN
ADRs/NNS
to/TO
VPA/NN
====================
Allele/DT
frequencies/NNS
of/IN
the/DT
MRP2/NN
polymorphisms/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
2/CD
./.
====================
Non-ADR/JJ
patients/NNS
were/VBD
more/RBR
likely/JJ
to/TO
have/VB
the/DT
deletion/NN
allele/NN
instead/RB
of/IN
the/DT
G/NN
allele/NN
at/IN
g.-1774/NN
when/WRB
compared/VBN
with/IN
patients/NNS
with/IN
CNS/NN
ADRs/NNS
(/(
p/NN
=/JJ
0.0057/CD
;/:
ADR/NN
,/,
20.7/CD
%/NN
;/:
non-ADR/JJ
,/,
37.3/CD
%/NN
)/)
./.
====================
The/DT
frequency/NN
of/IN
the/DT
T/NN
allele/NN
at/IN
g.-24/CD
was/VBD
higher/JJR
in/IN
patients/NNS
with/IN
CNS/NN
ADRs/NNS
than/IN
those/DT
without/IN
(/(
p/NN
=/JJ
0.0274/CD
;/:
ADR/NN
,/,
34.1/CD
%/NN
;/:
non-ADR/JJ
,/,
22.0/CD
%/NN
)/)
./.
====================
The/DT
difference/NN
between/IN
the/DT
groups/NNS
based/VBN
on/IN
g.-24C/NN
>/JJR
T/NN
frequencies/NNS
was/VBD
not/RB
significant/JJ
after/IN
Bonferroni/NNP
's/POS
correction/NN
,/,
while/IN
the/DT
difference/NN
based/VBN
on/IN
g.-1774delG/NN
frequencies/NNS
remained/VBD
significant/JJ
./.
====================
The/DT
genotype/NN
frequencies/NNS
of/IN
each/DT
polymorphism/NN
are/VBP
shown/VBN
in/IN
Table/JJ
3/CD
./.
====================
Genotype/NN
frequency/NN
distributions/NNS
were/VBD
consistent/JJ
with/IN
Hardy-Weinberg/JJ
equilibrium/NN
(/(
each/DT
p/NN
>/JJR
0.5/CD
)/)
./.
====================
The/DT
ADR/NN
group/NN
patients/NNS
were/VBD
more/RBR
likely/JJ
to/TO
have/VB
a/DT
GG/NNS
genotype/NN
than/IN
a/DT
deldel/JJ
genotype/NN
at/IN
g.-1774delG/NN
compared/VBN
to/TO
the/DT
non-ADR/JJ
group/NN
(/(
p/NN
=/JJ
0.023/CD
,/,
homo/NN
GG/NNS
and/CC
deldel/NN
p/NN
=/JJ
0.0146/CD
)/)
./.
====================
The/DT
TT/NN
and/CC
CT/NN
genotype/NN
frequencies/NNS
at/IN
g.-24C/NN
>/JJR
T/NN
were/VBD
higher/JJR
in/IN
patients/NNS
with/IN
CNS/NN
ADRs/NNS
than/IN
non-ADR/JJ
patients/NNS
(/(
p/NN
=/JJ
0.035/CD
,/,
hetero/RB
CT/NN
→/CD
TT/NN
p/NN
=/JJ
0.019/CD
)/)
./.
====================
The/DT
frequencies/NNS
of/IN
haplotypes/NNS
present/JJ
in/IN
at/IN
least/JJS
10/CD
%/NN
of/IN
the/DT
population/NN
are/VBP
presented/VBN
in/IN
Table/JJ
4/CD
./.
====================
Haplotype/NN
frequencies/NNS
of/IN
the/DT
MRP2/NN
polymorphisms/NNS
at/IN
all/DT
site/NN
./.
====================
The/DT
frequency/NN
of/IN
haplotype/JJ
1/CD
was/VBD
significantly/RB
higher/JJR
in/IN
patients/NNS
without/IN
CNS/NN
ADRs/NNS
(/(
32.3/CD
%/NN
)/)
than/IN
those/DT
with/IN
ADRs/NNS
(/(
15.8/CD
%/NN
)/)
(/(
p/NN
=/JJ
0.0039/CD
)/)
./.
====================
The/DT
frequency/NN
of/IN
haplotype/JJ
3/CD
was/VBD
higher/JJR
in/IN
patients/NNS
with/IN
CNS/NN
ADRs/NNS
than/IN
those/DT
without/IN
(/(
p/NN
=/JJ
0.0139/CD
)/)
,/,
but/CC
this/DT
difference/NN
was/VBD
no/DT
longer/RBR
significant/JJ
after/IN
Bonferroni/NNP
's/POS
correction/NN
was/VBD
applied/VBN
./.
====================
Measurement/JJ
of/IN
MRP2/NN
promoter/NN
activity/NN
====================
VPA/NN
stimulated/VBD
MRP2/NN
promoter/NN
activity/NN
about/RB
10-fold/RB
./.
====================
The/DT
epileptic/JJ
patients/NNS
with/IN
ADRs/NNS
of/IN
the/DT
CNS/NN
had/VBD
less/RBR
haplotype/JJ
1/CD
(/(
containing/VBG
g.-1774del/NN
)/)
than/IN
the/DT
epileptic/JJ
patients/NNS
with/IN
no/DT
ADRs/NNS
./.
====================
By/IN
inference/NN
,/,
the/DT
g.-1774G/NN
allele/NN
,/,
a/DT
major/JJ
allele/NN
of/IN
the/DT
MRP2/NN
promoter/NN
sequence/NN
,/,
was/VBD
associated/VBN
with/IN
ADRs/NNS
of/IN
the/DT
CNS/NN
in/IN
patients/NNS
treated/VBN
with/IN
VPA/NN
./.
====================
Epileptic/JJ
patients/NNS
with/IN
g.-1774del/NN
instead/RB
of/IN
g.-1774G/NN
were/VBD
more/RBR
likely/JJ
to/TO
be/VB
resistant/JJ
to/TO
VPA-related/JJ
ADRs/NNS
,/,
probably/RB
because/IN
the/DT
g.-1774del/NN
allele/NN
produced/VBN
higher/JJR
MRP2/NN
promoter/NN
activity/NN
than/IN
g.-1774G/NN
,/,
leading/VBG
to/TO
more/RBR
MRP2/NN
proteins/NNS
in/IN
the/DT
brain/NN
tissue/NN
after/IN
VPA/NN
treatment/NN
./.
====================
The/DT
presence/NN
of/IN
more/RBR
MRP2/NN
affected/VBN
the/DT
distribution/NN
of/IN
AEDs/NNS
(/(
especially/RB
VPA/NN
)/)
from/IN
the/DT
blood/NN
to/TO
the/DT
brain/NN
,/,
resulting/VBG
in/IN
the/DT
appearance/NN
of/IN
VPA-related/JJ
ADRs/NNS
in/IN
patients/NNS
with/IN
g.-1774G/NN
rather/RB
than/IN
g.-1774del/NN
./.
====================
Our/PRP$
luciferase/NN
assay/NN
data/NNS
supported/VBD
this/DT
hypothesis/NN
./.
====================
There/EX
was/VBD
no/DT
difference/NN
in/IN
luciferase/NN
activity/NN
between/IN
g.-1774del/NN
and/CC
the/DT
others/NNS
(/(
g.-1774G/NN
,/,
g.-24C/NN
>/JJR
T/NN
,/,
g.-1549G/NN
>/JJR
A/DT
)/)
with/IN
non-VPA/JJ
treatment/NN
./.
====================
Luciferase/NN
activity/NN
was/VBD
different/JJ
,/,
however/RB
,/,
following/VBG
3/CD
mM/NN
VPA/NN
treatment/NN
;/:
g.-1774del/NN
promoter/NN
(/(
haplotype/JJ
1/CD
)/)
activity/NN
was/VBD
134/CD
%/NN
higher/JJR
than/IN
g.-1774G/NN
promoter/NN
(/(
haplotype/JJ
2/CD
)/)
activity/NN
(/(
n/NN
=/JJ
5/CD
;/:
p/NN
</JJR
0.05/CD
by/IN
t-test/JJS
)/)
./.
====================
Further/RB
,/,
the/DT
g.-1774del/NN
MRP2/NN
promoter/NN
increased/VBD
1,014/NN
%/NN
with/IN
3/CD
mM/NN
VPA/NN
treatment/NN
compared/VBD
to/TO
non-VPA/JJ
treatment/NN
./.
====================
However/RB
,/,
the/DT
g.-1774G/NN
MRP2/NN
promoter/NN
also/RB
increased/VBD
816/CD
%/NN
with/IN
3/CD
mM/NN
VPA/NN
treatment/NN
compared/VBD
to/TO
non-VPA/JJ
treatment/NN
./.
====================
The/DT
change/NN
of/IN
g.-1774G/NN
→/CD
del/NN
increased/VBD
the/DT
expression/NN
of/IN
MRP2/NN
in/IN
neuronal/JJ
SH-SY5Y/NN
cells/NNS
treated/VBN
with/IN
3/CD
mM/NN
VPA/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Factors/NNS
influencing/VBG
ADRs/NNS
to/TO
VPA/NN
====================
Many/JJ
factors/NNS
,/,
including/VBG
gender/NN
;/:
age/NN
;/:
treatment/NN
with/IN
CBZ/NN
,/,
lamotrigine/NN
,/,
PHT/NN
,/,
or/CC
topiramate/NN
;/:
and/CC
HS/NN
,/,
did/VBD
not/RB
influence/VB
ADRs/NNS
./.
====================
The/DT
presence/NN
of/IN
the/DT
genotype/NN
G/G/NN
at/IN
the/DT
g.-1774/NN
region/NN
of/IN
the/DT
MRP2/NN
promoter/NN
influenced/VBD
ADRs/NNS
to/TO
VPA/NN
in/IN
epileptic/JJ
patients/NNS
./.
====================
Logistic/JJ
regression/NN
showed/VBD
that/IN
the/DT
G/G/NN
correlated/VBD
independently/RB
with/IN
ADRs/NNS
to/TO
VPA/NN
(/(
p/NN
</JJR
0.05/CD
;/:
OR/NN
,/,
9.102/CD
;/:
95/CD
%/NN
confidence/NN
interval/JJ
,/,
1.111/CD
to/TO
73.378/CD
)/)
./.
====================
The/DT
del/del/NN
allele/NN
was/VBD
the/DT
reference/NN
category/NN
(/(
Table/JJ
5/CD
)/)
./.
====================
The/DT
G/G/NN
genotype/NN
at/IN
g.-1774/NN
might/MD
influence/VB
lower/JJR
expression/NN
of/IN
MRP2/NN
than/IN
del/del/NN
in/IN
the/DT
brain/NN
,/,
leading/VBG
to/TO
ADRs/NNS
./.
====================
The/DT
selective/JJ
cellular/JJ
barrier/NN
controlling/VBG
drug/NN
delivery/NN
into/IN
the/DT
brain/NN
has/VBZ
been/VBN
identified/VBN
by/IN
the/DT
over-expression/NN
of/IN
MRP2/NN
in/IN
capillary/JJ
endothelia/NN
,/,
astrocytes/NNS
,/,
and/CC
neuronal/JJ
cells/NNS
in/IN
previous/JJ
studies/NNS
[/(
5/CD
,/,
26/CD
,/,
27/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
found/VBD
that/IN
the/DT
g.-1774del/NN
genotype/NN
in/IN
the/DT
promoter/NN
region/NN
up-regulated/VBD
the/DT
expression/NN
of/IN
MRP2/NN
./.
====================
Patients/NNS
with/IN
g.-1774del/NN
showed/VBD
resistance/NN
to/TO
ADRs/NNS
by/IN
increasing/VBG
the/DT
expression/NN
of/IN
MRP2/NN
,/,
followed/VBN
by/IN
a/DT
decrease/NN
of/IN
drug/NN
concentration/NN
in/IN
the/DT
brain/NN
./.
====================
Our/PRP$
data/NNS
supported/VBD
this/DT
hypothesis/NN
and/CC
verified/VBN
an/DT
association/NN
between/IN
g.-1774delG/NN
and/CC
ADR/NN
./.
====================
The/DT
difference/NN
of/IN
luciferase/NN
activity/NN
between/IN
g.-1774G/NN
and/CC
g.-1774del/NN
in/IN
neuronal/JJ
SH-SY5Y/NN
cells/NNS
was/VBD
not/RB
large/JJ
./.
====================
However/RB
,/,
they/PRP
showed/VBD
extensive/JJ
differences/NNS
by/IN
statistical/JJ
analysis/NN
(/(
p/NN
</JJR
0.05/CD
by/IN
t-test/JJS
)/)
./.
====================
Because/IN
the/DT
expression/NN
level/NN
of/IN
MRP2/NN
is/VBZ
lower/JJR
in/IN
brain/NN
neuronal/JJ
tissue/NN
than/IN
in/IN
hepatic/JJ
tissue/NN
,/,
even/RB
a/DT
little/JJ
change/NN
is/VBZ
thought/VBN
to/TO
be/VB
important/JJ
./.
====================
The/DT
luciferase/NN
assay/NN
of/IN
MRP2/NN
promoter/NN
activity/NN
has/VBZ
not/RB
been/VBN
conducted/VBN
in/IN
brain/NN
capillary/NN
endothelial/JJ
cells/NNS
yet/RB
./.
====================
In/IN
this/DT
cell/NN
line/NN
,/,
SNP/NN
function/NN
is/VBZ
thought/VBN
to/TO
be/VB
more/RBR
effective/JJ
,/,
since/IN
MRP2/NN
is/VBZ
more/RBR
highly/RB
expressed/VBN
in/IN
endothelial/JJ
cells/NNS
than/IN
in/IN
neuronal/JJ
cells/NNS
[/(
28/CD
]/)
./.
====================
In/IN
reality/NN
,/,
if/IN
MRP2/NN
and/CC
other/JJ
transporters/NNS
are/VBP
overexpressed/VBN
in/IN
the/DT
brain/NN
,/,
most/JJS
patients/NNS
should/MD
be/VB
not/RB
only/RB
non-ADR/JJ
but/CC
also/RB
resistant/JJ
to/TO
drug/NN
therapy/NN
./.
====================
However/RB
,/,
allele/NN
and/CC
genotype/NN
frequencies/NNS
of/IN
g.-1774delG/NN
were/VBD
not/RB
different/JJ
between/IN
drug-resistant/JJ
and/CC
drug-responsive/JJ
patients/NNS
(/(
p/NN
>/JJR
0.05/CD
)/)
./.
====================
The/DT
absence/NN
of/IN
a/DT
strict/JJ
definition/NN
of/IN
drug-resistant/JJ
epilepsy/NN
may/MD
have/VB
weakened/VBN
the/DT
statistical/JJ
analysis/NN
./.
====================
The/DT
selected/VBN
grouping/VBG
was/VBD
only/RB
a/DT
foundation/JJ
for/IN
retrospective/JJ
chart/NN
review/NN
./.
====================
If/IN
the/DT
definition/NN
was/VBD
stricter-for/IN
example/NN
,/,
at/IN
least/JJS
one/CD
seizure/NN
per/IN
year/NN
or/CC
non-seizure/JJ
over/IN
the/DT
year-the/DT
different/JJ
frequencies/NNS
of/IN
g.-1774delG/NN
within/IN
each/DT
group/NN
would/MD
have/VBP
been/VBN
more/RBR
significant/JJ
./.
====================
An/DT
accurate/JJ
study/NN
design/NN
and/CC
definitions/NNS
are/VBP
a/DT
key/JJ
part/NN
of/IN
effective/JJ
pharmacogenomic/JJ
studies/NNS
[/(
2/CD
]/)
./.
====================
Standards/NNS
for/IN
association/NN
studies/NNS
in/IN
pharmacogenomics/NNS
have/VBP
been/VBN
presented/VBN
in/IN
previous/JJ
studies/NNS
[/(
2/CD
]/)
./.
====================
In/IN
spite/NN
of/IN
the/DT
retrospective/JJ
study/NN
design/NN
,/,
an/DT
association/NN
with/IN
g.-1774delG/NN
was/VBD
noticeably/RB
significant/JJ
./.
====================
This/DT
SNP/NN
was/VBD
reported/VBN
previously/RB
in/IN
our/PRP$
group/NN
in/IN
relation/NN
to/TO
toxic/JJ
hepatitis/NN
[/(
24/CD
]/)
./.
====================
In/IN
that/DT
study/NN
,/,
the/DT
g.-1774del/NN
genotype/NN
caused/VBD
lower/JJR
expression/NN
of/IN
MRP2/NN
than/IN
g.-1774G/NN
in/IN
a/DT
human/JJ
hepatocyte-originated/JJ
cell/NN
line/NN
(/(
HepG2/NN
)/)
./.
====================
This/DT
finding/NN
is/VBZ
contrary/JJ
to/TO
the/DT
results/NNS
of/IN
the/DT
present/JJ
study/NN
./.
====================
There/EX
are/VBP
different/JJ
known/VBN
transcription/NN
factors/NNS
in/IN
hepatocytes/NNS
and/CC
neuronal/JJ
and/CC
endothelial/JJ
cells/NNS
./.
====================
The/DT
promoter/NN
activity/NN
in/IN
the/DT
cells/NNS
transfected/VBN
with/IN
a/DT
g.-1774G/JJ
(/(
haplotype/NN
2/CD
)/)
clone/NN
was/VBD
about/RB
100/CD
times/NNS
stronger/JJR
than/IN
those/DT
transfected/VBN
with/IN
the/DT
control/NN
vector/NN
in/IN
hepatic/JJ
cells/NNS
./.
====================
A/DT
strong/JJ
transcriptional/JJ
activator/NN
is/VBZ
present/JJ
in/IN
hepatocytes/NNS
./.
====================
However/RB
,/,
the/DT
difference/NN
in/IN
promoter/NN
activity/NN
between/IN
g.-1774G/NN
and/CC
mock/NN
control/NN
was/VBD
lower/JJR
in/IN
neuronal/JJ
SH-SY5Y/NN
cell/NN
lines/NNS
./.
====================
Neuronal/JJ
transcription/NN
factors/NNS
are/VBP
expected/VBN
to/TO
be/VB
weaker/JJR
than/IN
those/DT
in/IN
hepatocytes/NNS
./.
====================
The/DT
binding/NN
sequence/NN
is/VBZ
``/CD
AAAAACAACAAGATAA/NN
''/CD
(/(
the/DT
underlined/JJ
C/NN
is/VBZ
the/DT
anti-sense/JJ
sequence/NN
at/IN
g.-1774G/NN
)/)
./.
====================
Transcription/NN
factors/NNS
that/WDT
are/VBP
known/VBN
to/TO
bind/VB
this/DT
sequence/NN
are/VBP
GATA-1/NN
,/,
Evi-1/NN
,/,
FOXO/NN
,/,
HNF3/NN
,/,
and/CC
more/RBR
(/(
Genomatix/NN
software/JJ
GmbH/NN
)/)
./.
====================
Each/DT
tissue-specific/JJ
transcription/NN
factor/NN
binds/VBZ
this/DT
sequence/NN
and/CC
induces/VBZ
different/JJ
levels/NNS
of/IN
MRP2/NN
expression/NN
./.
====================
For/IN
example/NN
,/,
HNF3/NN
,/,
a/DT
common/JJ
activator/NN
in/IN
hepatocytes/NNS
,/,
was/VBD
thought/VBN
to/TO
activate/VB
MRP2/NN
expression/NN
through/IN
binding/NN
with/IN
g.-1774G/NN
rather/RB
than/IN
g.-1774del/NN
./.
====================
Consequently/RB
,/,
the/DT
expression/NN
of/IN
MRP2/NN
of/IN
g.-1774del/NN
would/MD
be/VB
lower/JJR
than/IN
g.-1774G/NN
./.
====================
In/IN
contrast/NN
,/,
if/IN
neuronal/JJ
cell/NN
transcriptional/JJ
activators/NNS
were/VBD
more/RBR
likely/JJ
to/TO
bind/VB
g.-1774del/NN
over/IN
g.-1774G/NN
,/,
neuronal/JJ
expression/NN
of/IN
MRP2/NN
of/IN
g.-1774del/NN
would/MD
be/VB
higher/JJR
than/IN
g.-1774G/NN
./.
====================
The/DT
factors/NNS
that/WDT
bind/VBP
to/TO
this/DT
region/NN
have/VBP
yet/RB
to/TO
be/VB
determined/VBN
./.
====================
Previous/JJ
studies/NNS
have/VBP
referred/VBN
to/TO
the/DT
different/JJ
binding/NN
factors/NNS
of/IN
this/DT
region/NN
in/IN
human/JJ
coronary/JJ
artery/NN
smooth/JJ
muscle/NN
cells/NNS
without/IN
specific/JJ
identification/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
a/DT
luciferase/NN
assay/NN
demonstrated/VBD
that/IN
VPA/NN
stimulated/VBD
the/DT
activity/NN
of/IN
the/DT
MRP2/NN
promoter/NN
in/IN
SH-SY5Y/NN
cells/NNS
./.
====================
VPA/NN
is/VBZ
a/DT
well-known/JJ
histone/NN
deacetylase/NN
(/(
HDAC/NN
)/)
inhibitor/NN
that/WDT
induces/VBZ
apoptosis/NN
in/IN
cancer/NN
cells/NNS
[/(
29/CD
,/,
30/CD
]/)
./.
====================
In/IN
normal/JJ
cells/NNS
,/,
however/RB
,/,
VPA/NN
activates/VBZ
chromosomal/JJ
transcriptional/JJ
ability/NN
by/IN
inhibiting/VBG
HDAC/NN
./.
====================
Chromosomal/JJ
DNA/NN
forms/NNS
a/DT
compact/NN
nucleosome/JJ
with/IN
histone/NN
proteins/NNS
and/CC
needs/VBZ
to/TO
be/VB
unpacked/JJ
in/IN
order/NN
to/TO
start/VB
transcription/NN
./.
====================
HDAC/NN
removes/VBZ
the/DT
acetyl/NN
group/NN
in/IN
acetyl-lysine/NN
residues/NNS
and/CC
biologically/RB
inhibits/VBZ
the/DT
activity/NN
of/IN
transcription/NN
[/(
31/CD
]/)
./.
====================
In/IN
neuronal/JJ
SH-SY5Y/NN
cells/NNS
,/,
VPA/NN
could/MD
activate/VB
the/DT
MRP2/NN
promoter/NN
by/IN
inhibiting/VBG
HDAC/NN
./.
====================
MRP2/NN
has/VBZ
farnesoid/JJ
X/NN
receptor/NN
,/,
retinoid/NN
X/NN
receptor/NN
(/(
RXR/NN
)/)
,/,
and/CC
peroxisome/NN
proliferator-activated/JJ
receptor/RXR/NN
binding/NN
regions/NNS
./.
====================
VPA/NN
interacts/VBZ
with/IN
these/DT
proteins/NNS
and/CC
regulates/VBZ
the/DT
expression/NN
level/NN
of/IN
MRP2/NN
protein/NN
[/(
32/CD
,/,
33/CD
]/)
./.
====================
P-gp/NN
polymorphisms/NNS
have/VBP
repeatedly/RB
been/VBN
associated/VBN
with/IN
drug/NN
response/NN
in/IN
epilepsy/NN
[/(
25/CD
,/,
34-37/CD
]/)
./.
====================
Up/IN
to/TO
now/RB
,/,
however/RB
,/,
the/DT
only/RB
functional/JJ
studies/NNS
of/IN
MRP2/NN
have/VBP
been/VBN
conducted/VBN
in/IN
a/DT
knockout/JJ
animal/NN
model/NN
[/(
38/CD
]/)
./.
====================
This/DT
report/NN
is/VBZ
the/DT
first/JJ
investigation/NN
to/TO
show/VB
an/DT
association/NN
between/IN
MRP2/NN
polymorphisms/NNS
and/CC
ADRs/NNS
in/IN
epilepsy/NN
./.
====================
These/DT
results/NNS
may/MD
be/VB
useful/JJ
in/IN
tailoring/VBG
AED/NN
medication/NN
./.
====================
The/DT
G/NN
allele/NN
of/IN
the/DT
MRP2/NN
promoter/NN
was/VBD
associated/VBN
with/IN
ADRs/NNS
to/TO
VPA/NN
in/IN
Korean/JJ
epileptic/JJ
patients/NNS
./.
====================
The/DT
del/NN
allele/NN
of/IN
MRP2/NN
protected/VBD
the/DT
brain/NN
against/IN
adverse/JJ
effects/NNS
of/IN
VPA/NN
by/IN
over-expressing/VBG
MRP2/NN
in/IN
brain/NN
neuronal/JJ
cells/NNS
./.
====================
These/DT
data/NNS
will/MD
help/VB
design/NN
therapy/NN
to/TO
minimize/VB
ADRs/NNS
in/IN
epileptic/JJ
patients/NNS
and/CC
aid/VB
in/IN
the/DT
development/NN
of/IN
new/JJ
AEDs/NNS
./.
====================
However/RB
,/,
further/RBR
independent/JJ
replication/NN
studies/NNS
are/VBP
needed/VBN
to/TO
unequivocally/RB
confirm/VBP
the/DT
association/NN
./.
====================
Luciferase/NN
activity/NN
of/IN
MRP2/NN
promoter/NN
variants/NNS
./.
====================
Valproic/JJ
acid/NN
(/(
VPA/NN
)/)
stimulated/VBD
MRP2/NN
promoter/NN
activity/NN
./.
====================
The/DT
g.-1774del/NN
(/(
-GCG/NN
)/)
variant/JJ
was/VBD
more/RBR
activated/VBN
than/IN
g.-1774G/NN
(/(
GGCG/NN
)/)
in/IN
cells/NNS
treated/VBN
with/IN
3/CD
mM/NN
VPA/NN
./.
====================
*p/RB
</JJR
0.05/CD
./.
====================
Demographic/JJ
characteristics/NNS
of/IN
epilepsy/NN
patients/NNS
treated/VBN
with/IN
VPA/NN
====================
Allele/DT
frequencies/NNS
of/IN
the/DT
MRP2/NN
polymorphisms/NNS
====================
Genotype/NN
distribution/NN
of/IN
MRP2/NN
variants/NNS
in/IN
control/NN
and/CC
epilepsy/NN
patients/NNS
====================
Frequency/NN
of/IN
MRP2/NN
haplotypes/NNS
in/IN
control/NN
and/CC
epilepsy/NN
patients/NNS
====================
Multiple/JJ
logistic/JJ
regression/NN
analysis/NN
for/IN
the/DT
determinants/NNS
of/IN
CNS/NN
ADRs/NNS
caused/VBD
by/IN
VPA/NN
====================
